Cell therapy substantially reduces severe rheumatoid arthritis in first clinical trial

The world's first clinical trial using CD19 CAR T-cell therapy for severe rheumatoid arthritis showed substantial disease activity reduction in all six patients, with half no longer needing medication by the end of the observation period.

This Wire brief sits within Fusion42's coverage of Biotech.